About 14 results

Leishmania is a parasite that disfigures or kills two million people every year in the developing world. There may be concerns about the efficacy and safety of current antileishmanial agents. In order to address this high-priority gap, Dr. Dawn Wetzel, Assistant Professor of Pediatrics and Pharmacology at UTSW, has identified a specific class of inhibitors with biological activity against Leishmania parasites. In order to support Dr. Wetzel’s antiparasitic screening efforts, Eisai Co., Ltd., has agreed to share inhibitors from this class of compounds.

Professor Fabrice Boyom, head of the Antimicrobial & Biocontrol Agents Unit (AmBcAU) at the University of Yaounde I, is working toward the discovery and development of novel drugs against HAT, Leishmaniasis, and Malaria by targeting the parasites’ critical metabolic pathways. To support Professor Boyom’s drug discovery efforts, Eisai will share dihydrofolate reductase (DHFR) inhibitors and potassium channel blockers.

University of Kansas provided Eisai researchers with expertise and ideas to address formulation challenges of Eisai’s anti-fungal compound.

Dr. Siqueira-Neto was interested in screening phosphodiesterase (PDE) V inhibitors for activity against kinetoplastids and schistosomes, as one compound of this class showed activity against a Trypanosoma cruzi PDE involved in osmoregulation. BVGH connected Dr. Siqueira-Neto with Eisai, which provided a select set of PDEV inhibitors for Dr. Siqueira-Neto to screen in cell-based and enzyme-based assays against Trypanosoma, Brugia, Leishmania, and Schistosoma.

Eisai will provide UCSD and NEU researchers with a targeted set of inhibitors and their structures to test against Leishmania spp. and T. cruzi.

Eisai will provide IDRI investigators with selected phosphodiesterase (PDE) V inhibitors and calcium channel blockers. The investigators will use IDRI's high-content imaging system to screen the compounds for activity against intracellular M. tuberculosis to identify candidates for further drug development.

Eisai will provide a UCSD researcher with inhibitors to screen against Leishmania, T. cruzi, S. mansoni, and Brugia.

Eisai will provide UCSD researchers with two targeted sets of inhibitors to screen against S. mansoni.

Eisai will provide an LSTM researcher with inhibitors to test against cerebral malaria.

Eisai will provide U Buea investigators with several classes of inhibitors including kinase inhibitors and calcium channel blockers. The investigators will screen the compounds for activity against Onchocerca adult worms to identify candidates for further drug development.